Axa
ITCI

Axa’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Axa’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-202,011
Closed -$6.93M – 1262
2019
Q4 		$6.93M Hold
202,011
– – 0.03% 535
2019
Q3 		$1.51M Buy
202,011
+69,500
+52% +$666K 0.01% 915
2019
Q2 		$1.72M Buy
132,511
+900
+0.7% +$11.5K 0.01% 872
2019
Q1 		$1.6M Buy
+131,611
New +$1.68M 0.01% 884
2016
Q3 		– Sell
-113,065
Closed -$4.39M – 1365
2016
Q2 		$4.39M Buy
+113,065
New +$4.06M 0.02% 589
2016
Q1 		– Sell
-7,200
Closed -$387K – 1433
2015
Q4 		$387K Buy
+7,200
New +$363K ﹤0.01% 1077

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Axa's ITCI Position: Q1 2020 in Review

Axa sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2020, closing a stake of 202,011 shares — an estimated $6.93M sold.

Axa first reported a position in ITCI in Q4 2015 and held it in 6 quarters. The position peaked at $6.93M in Q4 2019. 139 funds tracked by Wall St. Rank hold ITCI as of Q1 2020.

  • Axa reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2020 after selling out during the quarter.
  • Axa sold 202,011 Intra-Cellular Therapies Inc. shares in Q1 2020, an estimated $6.93M.
  • Axa first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 6 quarters.
  • Axa's Intra-Cellular Therapies Inc. position peaked at $6.93M in Q4 2019.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2020.

Based on Axa's 13F filing for Q1 2020, filed 15 May 2020.